Frequently Asked Questions


Q: Is HaploPharma a Contract Research Organization (CRO)?

A: We are able to adjust our business models in a flexible way to the need of our customers, but basically HaploPharma is not a CRO. We are striving to perform collaborative projects with our business partners and to share later the resulting IP.

Q: Is HaploPharma a drug company?
A: Currently we are not developing or producing own drugs. We are trying to support our partners’ drug development and application with our technology.

Q: Is ExpressGenotyping™ used for drug target discovery?
A: One might imagine of using ExpressGenotyping™ in a modified form also for target discovery. Our current main application, however, is targeting towards identification of genetic biomarkers to make development and application of a particular drug/candidate more efficient and safer.


Q: Why you are using mainly lymphoblastoid cell lines (LCL) for your ExpressGenotyping™ studies?
A: If special customer’s needs indicate the use of other cell types we of course can perform our ExpressGenotyping™ analyses with different cell types (e.g. hepatocytes) but our standard test system are LCLs. They are straightforward to use, give stable results, and well characterized cell lines are easily available through the International HapMap Project. Numbers of known genes correlated to drug efficacy and adverse effects have been detected by in-vitro ExpressGenotyping™ using LCLs. For example, known genes related to liver toxicity have been investigated in previous research using LCLs. It was shown that LCLs can be used in exploration of markers related to not only lymphoid cells but also other types of cells and organs.

Q: Are there already biomarkers out in clinical use that have been identified with ExpressGenotyping™?
A: We have currently several ExpressGenotyping™ studies running with very promising results, however, clinical development is lengthy, thus the time unfortunately is still too short for the identified biomarker candidates to reach already clinical validation and use.

Q: Can we use ExpressGenotyping™ only to support our later stages of clinical drug development?
A: You are not at all limited to this application. ExpressGenotyping™ can serve very well as a powerful tool in early preclinical development, e. g. for comparison and prioritization of drug lead candidates. It also can serve in exploratory research applications, e.g. to screen for genes regulated by cis-acting inheritable effects, to investigate genetic imprinting patterns on a genome-wide scale, and much more.

Q: Does HaploPharma provide access to banked clinical samples (e.g. tissues)?

A: Currently we are maintaining no own clinical sample depository. However, where applicable we can provide opportunities to access clinical samples under collaboration with academic and clinical scientists in Japan.

Q: We are currently performing a genome-wide association study (GWAS) for our drug. Is ExpressGenotyping™ of any use in such a case?
A: When performing a GWAS it is mostly possible to identify several genomic regions with various degrees of linkage to the investigated phenotype. It then has to be determined which of the various hits is a real hit. In such a situation ExpressGenotyping™ can be a powerful tool to evaluate the candidate genes/polymorphisms.